Skip to content

Ozone Therapy for the Treatment of Oral Mucositis in Patients Undergoing Radio and Chemotherapy in the Head and Neck Region

Ozone Therapy for the Treatment of Oral Mucositis in Patients Undergoing Radio and Chemotherapy in the Head and Neck Region: Retrospective Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07247799
Enrollment
38
Registered
2025-11-25
Start date
2025-09-01
Completion date
2026-01-20
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Neoplasms, Oral Mucositis

Brief summary

The present study aims to evaluate the effectiveness of a combined protocol of professional and at-home ozone therapy in the treatment of oral mucositis in patients undergoing radio- and/or chemotherapy. In-office treatment was performed using a medical ozone generator, while at-home therapy involved the daily application of high-concentration ozonated oil products. The study assessed the reduction in mucositis severity (WHO scale), decrease in pain (VAS scale), and improvement in patient-reported quality of life, with specific attention to nutrition, oral hygiene, and treatment adherence.

Interventions

Ozone DTA (Sweden \& Martina SpA, 35020 Due Carrare, PD, Italy) for clinical application; home oral care with DentO3® toothpaste, CollutO3®, Ozoral® Gel (Innovares, Sant'Ilario d'Enza (RE) - Italy).

Sponsors

Andrea Scribante
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years

Inclusion criteria

* patients undergoing radio and chemotherapy for head and neck cancer and cancers in other districts

Exclusion criteria

* syndromic patients * pregnant women * patients with cardiac pacemakers * epileptic patients * patients with high sensitivity to electric current

Design outcomes

Primary

MeasureTime frameDescription
WHO scale for oral mucositisAt baseline (T0), baseline after treatment (T1), after 48 hours (T2), at day five (T3), at day eight (T4), at day twelve (T5), at day fifteen (T6)Scoring criteria: * 0 None * 1 Oral soreness, erythema * 2 Oral erythema, ulcers, solid diet tolerated * 3 Oral ulcers, liquid diet only

Secondary

MeasureTime frameDescription
Visual Analogue ScaleAt baseline (T0), baseline after treatment (T1), after 48 hours (T2), at day five (T3), at day eight (T4), at day twelve (T5), at day fifteen (T6)Evaluation of self-perceived pain from 0 (no pain) to 10 (worst pain ever)
QuestionnaireAt baseline (T0) and at day fifteen (T6)Score from 0=best outcome to 10= worst outcome for the following items: * On a scale from 1 to 10, how much discomfort do certain foods and beverages cause you? * On a scale from 1 to 10, to what extent does your oral condition make you limit the intake of certain foods and beverages? * On a scale from 1 to 10, how much do certain food textures (e.g., crunchy foods) bother you? * On a scale from 1 to 10, to what extent does your oral condition lead you to limit the texture of the foods you consume? * On a scale from 1 to 10, how much discomfort does the temperature of certain foods and beverages cause you? * On a scale from 1 to 10, to what extent does your oral condition make you limit the temperature of the foods and beverages you consume? * On a scale from 1 to 10, how much does your oral condition cause discomfort during your daily oral activities? * On a scale from 1 to 10, how much discomfort does your oral condition cause during daily oral hygiene (brushin

Countries

Italy

Contacts

PRINCIPAL_INVESTIGATORAndrea Scribante, DDS, PhD

University of Pavia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026